Published in Biochemistry on June 27, 1978
Thrombin activity propagates in space during blood coagulation as an excitation wave. Biophys J (2012) 1.10
Human neutrophil elastase modulates platelet function by limited proteolysis of membrane glycoproteins. J Clin Invest (1985) 1.06
Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest (1986) 1.05
Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III. Gut (1988) 0.97
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest (1985) 0.94
Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model. Infect Immun (1993) 0.93
Cellular regulation of blood coagulation: a model for venous stasis. Blood (2010) 0.89
Regulation of factor Xa in vitro in human and mouse plasma and in vivo in mouse. Role of the endothelium and plasma proteinase inhibitors. J Clin Invest (1983) 0.86
Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II. Biochem J (1988) 0.83
Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III. Biochem J (1984) 0.83
Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J (1987) 0.82
A fragment of antithrombin that binds both heparin and thrombin. Biochem J (1986) 0.80
Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). Virchows Arch (2013) 0.80
Dynamics of Thrombin Generation and Flux from Clots during Whole Human Blood Flow over Collagen/Tissue Factor Surfaces. J Biol Chem (2016) 0.79
Relative quantification of several plasma proteins during liver transplantation surgery. J Biomed Biotechnol (2011) 0.77
Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci U S A (1985) 0.77
Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa. Biochem J (1989) 0.75
An acquired antithrombin autoantibody directed toward the catalytic center of the enzyme. J Clin Invest (1991) 0.75
Hirudin: Its Biology and Clinical Use. J Thromb Thrombolysis (1994) 0.75
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med (1987) 5.57
The estimation of polypeptide chain molecular weights by gel filtration in 6 M guanidine hydrochloride. J Biol Chem (1969) 4.77
Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet (1986) 4.04
Evidence of estrogen receptors in normal human osteoblast-like cells. Science (1988) 2.85
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem (1979) 2.54
The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med (1987) 2.43
Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med (1989) 2.43
Blood clotting in minimally altered whole blood. Blood (1996) 2.10
Chemical and physical properties of aequorin and the green fluorescent protein isolated from Aequorea forskålea. Biochemistry (1978) 2.10
Protein polypeptide chain molecular weights by gel chromatography in guanidinium chloride. Methods Enzymol (1972) 2.10
Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum (1990) 2.03
Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest (1976) 1.96
Prothrombin. Methods Enzymol (1976) 1.89
A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol (2001) 1.83
How factor VIIa works in hemophilia. J Thromb Haemost (2003) 1.81
Blood coagulation in hemophilia A and hemophilia C. Blood (1998) 1.76
Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A (1987) 1.75
"Normal" thrombin generation. Blood (1999) 1.74
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem (1994) 1.67
Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem (1987) 1.66
The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem (1994) 1.65
Physiochemical and biological properties of the major basic protein from guinea pig eosinophil granules. J Exp Med (1974) 1.61
Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation (2001) 1.61
Thrombin. Methods Enzymol (1976) 1.61
Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins. Biochemistry (1986) 1.57
Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. Biochemistry (1979) 1.55
Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood (2001) 1.54
Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost (2001) 1.54
Thrombin-catalyzed activation of single chain bovine factor V. J Biol Chem (1979) 1.53
The function of factor XI in tissue factor-initiated thrombin generation. J Thromb Haemost (2003) 1.53
Interaction of coagulation factor V and factor Va with platelets. J Biol Chem (1979) 1.53
A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem (1994) 1.53
Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem (1981) 1.49
Preparation and partial characterization of two forms of bovine thrombin. Biochem Biophys Res Commun (1975) 1.48
Immunologic quantitation of tissue factors. J Thromb Haemost (2006) 1.47
Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci U S A (1984) 1.46
Isolation and characterization of single chain bovine factor V. J Biol Chem (1979) 1.45
Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res (1990) 1.45
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thromb Haemost (2014) 1.44
Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem (1997) 1.44
Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost (2000) 1.44
Mathematical and biological models of blood coagulation. J Thromb Haemost (2005) 1.44
The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci (1994) 1.44
Factor V. Methods Enzymol (1981) 1.43
Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci U S A (1981) 1.40
Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem (1973) 1.39
Expression of human bone-related proteins in the hematopoietic microenvironment. J Clin Invest (1990) 1.38
Radioimmunoassay of factor V in human plasma and platelets. Blood (1982) 1.37
Respiratory effects of non-tobacco cigarettes: a longitudinal study in general population. Int J Epidemiol (1991) 1.36
Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J Clin Invest (1995) 1.36
Differentiation of metal ion-induced transitions of prothrombin fragment 1. J Biol Chem (1977) 1.35
The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost (2005) 1.35
Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem (1985) 1.34
The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem (1983) 1.34
Blood coagulation. Biochemistry (Mosc) (2002) 1.30
"Clotspeed," a mathematical simulation of the functional properties of prothrombinase. J Biol Chem (1984) 1.28
Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol (1999) 1.27
Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem (1992) 1.27
Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem (1983) 1.25
Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost (2007) 1.24
Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med (1985) 1.23
Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost (2005) 1.22
Isolation and characterization of native adult osteonectin. J Biol Chem (1985) 1.22
Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem (1997) 1.22
Thrombin generation: phenotypic quantitation. J Thromb Haemost (2004) 1.22
Primary structure of human prethrombin 2 and alpha-thrombin. J Biol Chem (1977) 1.21
The regulation of clotting factors. Crit Rev Eukaryot Gene Expr (1997) 1.21
USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol (1989) 1.20
Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost (2005) 1.19
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood (2000) 1.18
Single-chain nature of human serum transferrin. Biochemistry (1970) 1.18
Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry (1979) 1.18
Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem (1988) 1.17
The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation. J Biol Chem (1973) 1.17
Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem (1982) 1.16
Characterization of Factor V activation intermediates. J Biol Chem (1984) 1.15
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood (1997) 1.14
Multiple active forms of thrombin. IV. Relative activities of meizothrombins. J Biol Chem (1990) 1.13
Kinetics of human factor VII activation. Biochemistry (1996) 1.13
Prothrombin. Methods Enzymol (1981) 1.13
Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci U S A (1986) 1.12
Cofactor dependence of factor Xa incorporation into the prothrombinase complex. J Biol Chem (1981) 1.12
Human prothrombin activation. J Biol Chem (1975) 1.12
Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem (1991) 1.11
Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab (1983) 1.11
The binding of activated protein C to factors V and Va. J Biol Chem (1986) 1.09
Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.09
Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem (1997) 1.08
Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab (1988) 1.08
Human platelets contain and secrete osteonectin, a major protein of mineralized bone. Proc Natl Acad Sci U S A (1986) 1.07
Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest (1986) 1.07
Multiple active forms of thrombin. II. Mechanism of production from prothrombin. J Biol Chem (1971) 1.07
The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem (1986) 1.07
Characterization of the molecular defect in factor VR506Q. J Biol Chem (1995) 1.05
Zymogen/enzyme discrimination using peptide chloromethyl ketones. J Biol Chem (1989) 1.04
The factor Xa-catalyzed activation of factor V. J Biol Chem (1983) 1.04